ToPCaP's long term goal is to substantially decrease prostate cancer morbidity and mortality through the identification of prognostic biomarkers and the initiation of appropriate lifestyle changes before or after diagnosis of the disease. In the process of distinguishing between indolent and aggressive disease, ToPCaP strives to reduce unnecessary and potentially dangerous treatments for low-risk prostate cancers. The projects highlighted are research initiatives aimed at achieving our objective.